Gout | Treatment Algorithms | Claims Data Analysis | US | 2018
Gout is a chronic condition characterized by intermittent acute flares caused by elevated serum uric acid (sUA). Treatment of the painful acute flares is distinct from the chronic management of hyperuricemia with urate-lowering therapies and is not considered in this study. Xanthine oxidase inhibitors (XOIs) are the mainstay of chronic gout treatment, with generic allopurinol prescribed much more extensively than the brands Uloric and Zurampic. Gout Treatment Algorithms presents urate-lowering therapy prescribing patterns and provides insights into the uptake of novel branded agents against the background of generic allopurinol dominance.
QUESTIONS ANSWERED:
- What patient share do key therapies and brands garner by line of therapy in newly diagnosed gout patients? What are the quarterly trends in prescribing among recently-treated and new diagnosed gout patients?
- How has Zurampic and Krystexxa been integrated into the treatment algorithm?
- What proportion of gout patients receive drug therapy within one year of diagnosis, and how quickly?
- What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of gout patients are treated with monotherapy versus combination therapy?
- What are the most widely used combination therapies?
- What are the product-level compliance and persistency rates among drug-treated patients with gout?
Related Market Assessment Reports
Report
Multiple Sclerosis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Multiple Sclerosis (US)
The multiple sclerosis (MS) therapy market comprises more than 20 immunomodulatory disease-modifying therapies (DMTs), and more are in the pipeline. A variety of drug classes each hold a niche…
Report
Systemic Lupus Erythematosus – Access & Reimbursement – Access & Reimbursement – Systemic Lupus Erythematosus (US)
The U.S. systemic lupus erythematosus (SLE) therapy market is largely genericized and off-label. With the exception of GSK’s Benlysta, the firstagents approved for the indication in almost 60…
